Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease

ConditionHematological Neoplasms

Trial statusRecruiting

Trial phasePhase 4

Trial typeInterventional

Biological sexAll

Age1-18

SponsorWei Zhao

About this trial

The investigators' purpose was to assess the feasibility of dosage individualization of the commonly used antineoplastic drugs and anti-infective drugs in children with hematoplastic disease.

Eligibility criteria

Qualifiers

Patients must be diagnosed with hematological neoplasms

Antineoplastic drugs or anti-infective drugs used as part of regular treatment

Disqualifiers

expected survival time less than the treatment cycle;

patients with other factors that researcher considers unsuitable for inclusion.

Trial design

Treatments tested in this trial

Bortezomib
Eltrombopag
Imatinib
dasatinib
Pegaspargase
Anti-Infective Drugs
PEGylated Recombinant Human Granulocyte Colony-Stimulating Factor

Treatment groups

1,500 Participants

are divided into 1 treatment group

Locations

Department of Pediatrics, the Affiliated Hospital of Xuzhou Medical University221000, XuzhouJiangsu, China

State Key Laboratory of Experimental Haematology, Department of Paediatric Haematology, Institute of Haematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College300020, TanjinTianjin Municipality, China

Sponsors and collaborators

Wei Zhao

Lead sponsor

Shandong University

Sponsor institution

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Collaborator

Source ClinicalTrials.gov